US-EN
Select Country

Magnetic Resonance Imaging

      

Selecting the right contrast is critical.
That’s why Bracco offers two gadolinium-based contrast agents (GBCA) for MRI of the CNS in adult and pediatric patients, and MultiHance for MR angiography (MRA) to evaluate adults with known or suspected renal or aorto-ilio-femoral occlusive vascular disease, letting you choose the right product for each patient.

MultiHance is the MR contrast agent with the highest relaxivity among those approved for use in MRI of CNS lesions and the first extracellular approved for MRA in adults in the U.S.. Or select ProHance®, the first macrocyclic GBCA that provides high kinetic and conditional stability.6,7  With a combined 31 million doses administered worldwide, Bracco delivers proven solutions that allow you to choose the right product for every patient.8

Learn More about the TRUTH Study1
Link to abstract: http://www.ncbi.nlm.nih.gov/pubmed/25300984

Reference 1. Maravilla KR, Smith MP, Vymazal J, Goyal M, Herman M, Baima JJ, Babbel R, Vaneckova M, Zižka J, Colosimo C, Urbańczyk-Zawadzka M, Mechl M, Bag AK, Bastianello S, Bueltmann E, Hirai T, Frattini T, Kirchin MA, Pirovano G. Are There Differences between Macrocyclic Gadolinium Contrast Agents for Brain Tumor Imaging? Results of a Multicenter Intraindividual Crossover Comparison of Gadobutrol with Gadoteridol (the TRUTH Study). AJNR Am J Neuroradiol. 2014 Oct 9. [Epub ahead of print]

 

 

REFERENCES: 1. MultiHance (gadobenate dimeglumine) injection, 529 mg/mL full Prescribing Information. Princeton, NJ: Bracco Diagnostics Inc. July 2012. 2 Bleicher AG, Kanal E. A serial dilution study of gadolinium-based MR imaging contrast agents. AJNR. 2008;29:668-73. 3. Pintaske J, et al. Relaxivity of gadopentetate dimeglumine (Magnevist), gadobutrol (Gadovist), and gadobenate dimeglumine (MultiHance) in human blood plasma at 0.2, 1.5 and 3 Tesla.Erratum Invest. Radiol. 2006;41:213-221 4. Rohrer M, et al. Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths. Invest. Radiol. 2005;40:715-724. 5. Kirchin MA, et al. Gadobenate dimeglumine (Gd-BOPTA). An overview. Invest. Radiol. 1998;33(11):798-809. 6. Idee JM, Port C, Raynal I, et al. Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a review. Fundamental and Clinical Pharmacology. 2006; 20:563-576. 7. ProHance (gadoteridol) injection 279.3 mg/mL full Prescribing Information. Princeton, NJ: Bracco Diagnostics Inc.; Sept 2011. 8. Postmarketing Surveillance and Utilization Report 2010. On file, Bracco Diagnostics Inc.

All trademarks and registration trademarks are the property of the respective owners.

MULTIHANCE highest Relaxivity

MultiHance:
The Highest Relaxivity
Agent for CNS MRI.

Read more

PROHANCE HIGH STABILITY

By all measures,
ProHance is an
exceptionally stable
Gd chelate.
Learn more!

Read more

Acist

ACIST® Medical
Systems is a market
leader in advanced
contrast imaging
systems for
cardiovascular
angiography.

Visit the site

Find Your Rep

Enter your ZIP code in the box below:

logoThe first and only contrast agent indicated for both MRI of the CNS (>2 years) and MRA (adults) in the U.S.
The first macrocyclic gadolinium MRI contrast agent approved in the U.S. for CNS MRI.
EmpowerMr logoEmpowerMR® Contrast Injection System. World's first hydraulic-powered MR injector eliminates batteries and associated issues.

MULTIHANCE INDICATIONS AND USAGE:
MultiHance is a gadolinium-based contrast agent indicated for use in:

  • Magnetic resonance imaging (MRI) of the central nervous system (CNS) in adults and children over 2 years of age to visualize lesions with abnormal blood-brain b arrier or abnormal vascularity of the brain, spine, and associated tissues and
  • Magnetic resonance angiography (MRA) to evaluate adults with known or suspected renal or aorto-ilio-femoral occlusive vascular disease

IMPORTANT SAFETY INFORMATION

WARNING: NEPHROGENIC SYSTEMIC FIBROSIS

Gadolinium-based contrast agents (GBCAs) increase the risk for NSF among patients with impaired elimination of the drugs. Avoid use of GBCAs in these patients unless the diagnostic information is essential and not available with non-contrasted MRI or other modalities. NSF may result in fatal or debilitating systemic fibrosis affecting the skin, muscle and internal organs.

  • The risk for NSF appears highest among patients with:
    • chronic, severe kidney disease (GFR <30 mL/min/1.73m2), or
    • acute kidney injury.
  • Screen patients for acute kidney injury and other conditions that may reduce renal function. For patients at risk for chronically reduced renal function (e.g. age > 60 years, hypertension or diabetes), estimate the glomerular filtration rate (GFR) through laboratory testing.
  • For patients at highest risk for NSF, do not exceed the recommended MultiHance dose and allow a sufficient period of time for elimination of the drug from the body prior to re-administration [See Warnings and Precautions (5.1)]

Anaphylactic and anaphylactoid reactions have been reported, involving cardiovascular, respiratory, and/or cutaneous manifestations ranging from mild to severe. The possibility of a reaction should always be considered, especially in those patients with a history of a known clinical hypersensitivity or a history of asthma or other allergic disorders.

Please consult full Prescribing Information for MultiHance including boxed WARNING contained within this website.

PROHANCE INDICATIONS AND USAGE
Central Nervous System
ProHance (Gadoteridol) Injection is indicated for use in MRI in adults and children over 2 years of age to visualize lesions with abnormal vascularity in the brain (intracranial lesions), spine and associated tissues.

Extracranial/Extraspinal Tissues
ProHance is indicated for use in MRI in adults to visualize lesions in the head and neck.

IMPORTANT SAFETY INFORMATION

WARNING: NEPHROGENIC SYSTEMIC FIBROSIS

Gadolinium-based contrast agents (GBCAs) increase the risk for NSF among patients with impaired elimination of the drugs. Avoid use of GBCAs in these patients unless the diagnostic information is essential and not available with non-contrasted MRI or other modalities. NSF may result in fatal or debilitating systemic fibrosis affecting the skin, muscle and internal organs.

  • The risk for NSF appears highest among patients with:
    • chronic, severe kidney disease (GFR <30 mL/min/1.73m2), or
    • acute kidney injury.
  • Screen patients for acute kidney injury and other conditions that may reduce renal function. For patients at risk for chronically reduced renal function (e.g. age > 60 years, hypertension or diabetes), estimate the glomerular filtration rate (GFR) through laboratory testing.
  • For patients at highest risk for NSF, do not exceed the recommended ProHance dose and allow a sufficient period of time for elimination of the drug from the body prior to re-administration [See Warnings]

As with all paramagnetic agents, caution should be exercised in patients with deoxygenated sickle erythrocytes and renal insufficiency with or without hepatic impairment. The possibility of a reaction, including serious, life threatening, or fatal, anaphylactic or cardiovascular reactions, or other idiosyncratic reactions, should always be considered, especially in those patients with a history of a known clinical hypersensitivity or a history of asthma or other allergic disorders.

Please consult full Prescribing Information for ProHance including boxed WARNING contained within this website.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

All trademarks and registered trademarks are the property of their respective owners.

MultiHance®is manufactured for Bracco Diagnostics Inc. by BIPSO GmbH – 78224 Singen (Germany) and by Patheon Italia SpA, Ferentino, Italy.
ProHance®is manufactured for Bracco Diagnostics Inc. by BIPSO GmbH – 78224 Singen (Germany).